Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease

Trial Profile

A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prasugrel (Primary)
  • Indications Embolism and thrombosis; Sickle cell anaemia; Veno-occlusive disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms DOVE; TADO
  • Sponsors Eli Lilly
  • Most Recent Events

    • 12 Dec 2017 Results of evaluation of candidate gene variants and impact of these variants on prasugrel treatment response presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2016 Results published in the Thrombosis and Haemostasis
    • 06 Dec 2016 Results assessing effect of geographical region and age group on vaso-occlusive crisis (VOC) events, analgesic use, the rate, intensity, and perception of pain in children with sickle cell anaemia, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top